ToxStrategies is pleased to announce the establishment of The Center of Excellence for 21st Century Toxicology (21CT). The Center will focus on supporting the transition in toxicological science to in vitro and computational toxicology through the design and implementation of 21st century methods in risk assessment. 21CT is designed to be a science hub, providing expertise in cell-based science, computational toxicology, targeted in vivo studies, pharmacokinetics, in vitro–to–in vivo extrapolation (IVIVE), rapid exposure assessment, systematic literature reviews for evidence-based toxicology, and Adverse Outcome Pathway–based safety assessments. 21CT’s mission is to help guide our clients through the rapidly changing regulatory landscape that is affecting many business sectors, including the chemical, agrichemical, consumer products, pharmaceutical, and cosmetics industries, and to lead the way in the conduct of in vitro–based safety assessments.
The Center will be led by Drs. Susan Borghoff and Miyoung Yoon. Dr. Borghoff has expertise in identifying modes of action for endocrine-active chemicals, respiratory toxicants, and carcinogens, and applying pharmacokinetic modeling in risk assessment. Dr. Borghoff focuses her broad toxicology experience on incorporating data generated using new 21st century tools and technologies to replace traditional approaches, supporting both discovery and regulatory needs. Dr. Yoon is an internationally recognized expert in the field of quantitative IVIVE, a crucial element in 21st century safety sciences. Dr. Yoon is involved in developing and applying novel in vitro metabolism and biokinetic assays and extrapolation modeling (IVIVE) approaches to risk and safety assessment of chemicals and drugs.